RET
About
Location: 10q11.21
Mappings
Biomarkers
RET is involved in the following curated biomarkers.
| Name | Biomarker type | Propositions | Statements |
|---|---|---|---|
| RET p.M918T | Somatic Variant | 1 | 1 |
| v::RET | Rearrangement | 7 | 10 |
| RET oncogenic variants | Somatic Variant | 1 | 1 |
Therapeutic response
Precision oncology relationships for therapeutic response involving this gene.
| Organization(s) | Biomarker(s) | Cancer type | Therapy(ies) | |
|---|---|---|---|---|
| EMA (1) | RET p.M918T | Medullary Thyroid Cancer | Selpercatinib | |
| EMA (1) FDA (1) | v::RET | Non-Small Cell Lung Cancer | Pralsetinib | |
| FDA (1) | v::RET | Papillary Thyroid Cancer | Pralsetinib | |
| EMA (1) FDA (1) | v::RET | Non-Small Cell Lung Cancer | Selpercatinib | |
| FDA (1) | v::RET | Anaplastic Thyroid Cancer | Selpercatinib | |
| EMA (1) FDA (1) | v::RET | Any solid tumor | Selpercatinib | |
| EMA (1) | v::RET | Medullary Thyroid Cancer | Vandetanib | |
| EMA (1) | v::RET | Papillary Thyroid Cancer | Selpercatinib | |
| FDA (1) | RET oncogenic variants | Medullary Thyroid Cancer | Selpercatinib |